Scarica l'app Stockscreener
3.0969
4.74%
-0.1631
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$3.26
Aprire:
$3.3
Volume 24 ore:
235.43K
Relative Volume:
0.10
Capitalizzazione di mercato:
$149.27M
Reddito:
-
Utile/perdita netta:
$-97.22M
Rapporto P/E:
-2.2441
EPS:
-1.38
Flusso di cassa netto:
$-82.44M
1 W Prestazione:
-18.28%
1M Prestazione:
-14.45%
6M Prestazione:
+92.88%
1 anno Prestazione:
-88.15%
Intervallo 1D:
$3.09
$3.32
Intervallo di 1 settimana:
$3.10
$3.81
Portata 52W:
$1.15
$33.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Nome
Cassava Sciences Inc
Settore
Industria
Telefono
512-501-2444
Indirizzo
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Confronta SAVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
3.09 | 157.48M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-27 | Iniziato | B. Riley Securities | Buy |
| 2021-02-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Downgrade | Maxim Group | Buy → Hold |
| 2020-01-10 | Reiterato | Maxim Group | Buy |
Mostra tutto
Cassava Sciences Inc Borsa (SAVA) Ultime notizie
What risks investors should watch in Cassava Sciences Inc. stock2025 Fundamental Recap & Weekly Momentum Stock Picks - newser.com
Is it too late to sell Cassava Sciences Inc.July 2025 Fed Impact & Community Shared Stock Ideas - newser.com
Will Cassava Sciences Inc. Equity Warrant stock deliver shareholder valueBear Alert & Daily Stock Trend Watchlist - newser.com
Is Cassava Sciences Inc. Equity Warrant stock bottoming outInsider Buying & Reliable Momentum Entry Alerts - newser.com
Will Cassava Sciences Inc. continue its uptrendWeekly Market Report & Community Consensus Picks - newser.com
Why analysts upgrade Cassava Sciences Inc. stock2025 Trade Ideas & Reliable Intraday Trade Alerts - newser.com
Is Cassava Sciences Inc. stock a buy on dipsGDP Growth & Weekly Market Pulse Alerts - newser.com
Can Cassava Sciences Inc. stock attract ESG capital inflowsEarnings Beat & Stock Portfolio Risk Control - newser.com
Tools to monitor Cassava Sciences Inc. Equity Warrant recovery probabilityTrade Risk Report & Daily Stock Trend Reports - newser.com
Full technical analysis of Cassava Sciences Inc. stockEarnings Miss & Advanced Technical Signal Analysis - newser.com
Is Cassava Sciences Inc. Equity Warrant stock affected by interest rate hikesAnalyst Downgrade & Stepwise Entry and Exit Trade Signals - newser.com
Will Cassava Sciences Inc. Equity Warrant stock benefit from sector rotationM&A Rumor & Verified Swing Trading Watchlists - newser.com
Why Cassava Sciences Inc. Equity Warrant stock is a value investor pickM&A Rumor & Stock Portfolio Risk Control - newser.com
Can Cassava Sciences Inc. (PX91) stock ride next bull market cycleSell Signal & Technical Analysis for Trade Confirmation - newser.com
Why Cassava Sciences Inc. (PX91) stock could be next leaderEarnings Recap Summary & AI Enhanced Trading Alerts - newser.com
Will Cassava Sciences Inc. stock go up soon2025 Risk Factors & Consistent Growth Equity Picks - newser.com
Will Cassava Sciences Inc. Equity Warrant stock keep outperforming rivalsMarket Growth Summary & Real-Time Sentiment Analysis - newser.com
How strong is Cassava Sciences Inc. stock revenue growth2025 EndofYear Setup & Safe Capital Allocation Plans - newser.com
What analysts say about Maywood Acquisition Corp stockRelative Strength Index (RSI) & Budget Friendly Trading Strategies - earlytimes.in
Risk adjusted return profile for Cassava Sciences Inc. analyzed2025 Investor Takeaways & Expert Verified Movement Alerts - newser.com
Cassava Sciences Inc. Equity Warrant stock volume spike explainedWeekly Gains Summary & High Return Trade Opportunity Guides - newser.com
Why Cassava Sciences Inc. stock is in analyst buy zoneMarket Activity Report & Safe Entry Momentum Tips - newser.com
Chart overlay techniques for tracking Cassava Sciences Inc.July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
How institutional ownership impacts Cassava Sciences Inc. Equity Warrant stockQuarterly Trade Report & Breakout Confirmation Alerts - newser.com
Can Cassava Sciences Inc. Equity Warrant stock maintain operating marginsJuly 2025 Fed Impact & AI Optimized Trading Strategy Guides - newser.com
Will Cassava Sciences Inc. (PX91) stock benefit from mergersMarket Sentiment Summary & Proven Capital Preservation Methods - newser.com
Cassava Sciences (NASDAQ:SAVA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
What the charts say about Cassava Sciences Inc. today2025 Trading Volume Trends & Daily Growth Stock Investment Tips - newser.com
Why Cassava Sciences Inc. is moving todayJuly 2025 Decliners & Precise Entry and Exit Recommendations - newser.com
Cassava Sciences Inc Azioni (SAVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cassava Sciences Inc Azioni (SAVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
| Kupiec James William | Chief Medical Officer |
Nov 29 '24 |
Sale |
3.87 |
4,000 |
15,480 |
0 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.21%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):